%0 Journal Article
%T Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
%A Song GY
%A Kim HJ
%A Kim T
%A Ahn SY
%A Jung SH
%A Kim M
%A Yang DH
%A Lee JJ
%A Kim MY
%A Cheong JW
%A Jung CW
%A Jang JH
%A Kim HJ
%A Moon JH
%A Sohn SK
%A Won JH
%A Park SK
%A Kim SH
%A Choi CK
%A Kim HJ
%A Ahn JS
%A Kim DDH
%J Sci Rep
%V 14
%N 1
%D 2024 04 12
%M 38609396
%F 4.996
%R 10.1038/s41598-024-57295-5
%X This study aimed to validate the 2022 European LeukemiaNet (ELN) risk stratification for acute myeloid leukemia (AML). A total of 624 newly diagnosed AML patients from 1998 to 2014 were included in the analysis. Genetic profiling was conducted using targeted deep sequencing of 45 genes based on recurrent driver mutations. In total, 134 (21.5%) patients had their risk classification reassessed according to the 2022 ELN risk stratification. Among those initially classified as having a favorable risk in 2017 (n = 218), 31 and 3 patients were reclassified as having intermediate risk or adverse risk, respectively. Among the three subgroups, the 2022 ELN favorable-risk group showed significantly longer survival outcomes than the other groups. Within the 2017 ELN intermediate-risk group (n = 298), 21 and 46 patients were reclassified as having favorable risk or adverse risk, respectively, and each group showed significant stratifications in survival outcomes. Some patients initially classified as having adverse risk in 2017 were reclassified into the intermediate-risk group (33 of 108 patients), but no prognostic improvements were observed in this group. A multivariable analysis identified the 2022 ELN risk stratification, age, and receiving allogeneic hematopoietic cell transplantation as significant prognostic factors for survival. The 2022 ELN risk stratification enables more precise decisions for proceeding with allogeneic hematopoietic cell transplantation for AML patients.